SEC Comment Letter 0000000000-24-004834 to MANGOCEUTICALS, INC. (MGRX)
MANGOCEUTICALS, INC.
Date: April 30, 2024 · CIK: 0001938046 · Accession: 0000000000-24-004834
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-278888
Letter
United States securities and exchange commission logo April 30, 2024 Jacob D. Cohen Chief Executive Officer Mangoceuticals, Inc. 15110 N. Dallas Parkway, Suite 600 Dallas, TX 75248 Re:Mangoceuticals, Inc. Registration Statement on Form S-1 Filed April 23, 2024 File No. 333-278888 Dear Jacob D. Cohen: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Juan Grana at 202-551-6034 with any questions. Sincerely, Division of Corporation Finance Office of Industrial Applications and Services cc: Joseph M. Lucosky, Esq.
Show Raw Text
United States securities and exchange commission logo
April 30, 2024
Jacob D. Cohen
Chief Executive Officer
Mangoceuticals, Inc.
15110 N. Dallas Parkway, Suite 600
Dallas, TX 75248
Re:Mangoceuticals, Inc.
Registration Statement on Form S-1
Filed April 23, 2024
File No. 333-278888
Dear Jacob D. Cohen:
This is to advise you that we have not reviewed and will not review your registration
statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Juan Grana at 202-551-6034 with any questions.
Sincerely,
Division of Corporation Finance
Office of Industrial Applications and
Services
cc: Joseph M. Lucosky, Esq.